Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T18:46:09.419Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacotherapy of dysthymia: review and new findings

Published online by Cambridge University Press:  16 April 2020

M Versiani ,
AE Nardi  and
I Figueira
M Versiani*
Affiliation:
Institutional Affiliation, Institute of Psychiatry, Federal University of Rio de Janeiro, Anxiety and Depression Research Program, Rio de Janeiro, Brazil
AE Nardi
Affiliation:
Institutional Affiliation, Institute of Psychiatry, Federal University of Rio de Janeiro, Anxiety and Depression Research Program, Rio de Janeiro, Brazil
I Figueira
Affiliation:
Institutional Affiliation, Institute of Psychiatry, Federal University of Rio de Janeiro, Anxiety and Depression Research Program, Rio de Janeiro, Brazil
*
*Address for correspondence and reprints: Rua Visconde de Pirajá 407 sala 805, Ipanema, Rio de Janeiro - RJ, Brazil, CEP - 22410-003.
Get access

Summary

Open trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a combination of amitryptiline plus chlordiazepoxide is described. After discontinuation there was a relapse rate of 89.1%. The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Sertraline was studied vs placebo or imipramine in primary dysthymia. Moclobemide, imipramine and placebo were also studied in 315 patients. Mean doses were 650 mg/d of moclobemide and 203.2 mg/d of imipramine. Moclobemide and sertraline were both efficacious and well tolerated. In a long term treatment the clinician should assess the risk-benefit ratio. Dysthymic patients are very sensitive to unwanted effects and compliance is a serious issue.

Keywords

dysthymiadysthymic disorderdrug treatment
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue 4 , July 1998 , pp. 203 - 209
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anonymous Dysthymia in clinical practice, the WPA dysthymia working group. Br J Psychiatry 1995; 166: 174–183CrossRefGoogle Scholar
Akiskal, HLa dysthymie et son traitement. Encephale 1993; 19: 375–378Google Scholar
Akiskal, HSA proposed clinical approach to chronic and “resistant” depressions: evaluation and treatment. J Clin Psychiatry 1985; 46: 32–37Google ScholarPubMed
Akiskal, HSChronic depression. Bull Menninger Clin 1991; 55: 156–171Google ScholarPubMed
Akiskal, HSDysthymia, clinical and external validity. Acta Psychiatr Scand Suppl 1994; 383: 19–23CrossRefGoogle ScholarPubMed
Akiskal, HS, Weise, REThe clinical spectrum of so-called “minor” depressions Am J Psychother 1992 46 9–22CrossRefGoogle ScholarPubMed
American Psychiatric Association 3rd revised editio. Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Press; 1987Google Scholar
American Psychiatric Association 4th edition. Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Press; 1994Google Scholar
Angst, J, Wicki, WThe Zurich study. XI. Is dysthymia a separate form of depression? Results of the Zurich cohort study. Eur Arch Psychiatry Clin Neurosci 1991; 240: 349–354CrossRefGoogle ScholarPubMed
Ardito, R, Cecchini, S, Rama, SDurata del trattamento antidepressivo. Ricadute e loro prevenzione. Minerva Med 1977; 68: 1667–1674Google Scholar
Auby, P, Olivier, F, Schmitt, L, Peresson, G, Moron, PInhibiteurs calciques et troubles dysthymiques. Données récentes. Encephale 1992; 18: 67–69Google Scholar
Bakish, D, Lapierre, YD, Weinstein, R, et al.Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993; 13: 409–414CrossRefGoogle ScholarPubMed
Barrett, JENaturalistic change after 2 years in neurotic depressive disorders (RDC categories). Compr Psychiatry 1984; 25: 404–418CrossRefGoogle Scholar
Benichou, L, Pialloux, GLithium et dysthymies. Pratique ambulatoire. Bord Med 1972; 5: 673–678Google Scholar
Berbescu, CTratamentul cu litiu in boala distimica a copilului si adolescentului. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir 1996; 31: 3Google Scholar
Bersani, G, Pozzi, F, Marini, S, Grispini, A, Pasini, A, Ciani, N5-ht2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83: 244–248CrossRefGoogle ScholarPubMed
Bonasegla, F, Cavalca, GG, Rossini, RAzione dei sali di litio sugli stati distimici in soggetti ipertiroidei. Riv Sper Freniatr 1969; 93: 1328–1336Google Scholar
Cedrola, G, Amati, A, Del Vecchio, M, Camardese, M, Kemali, DRilievi clinici sull'azione terapeutica del litio carbonato nelle psicosi distimiche. Osp Psichiatr 1970; 38: 359–372Google Scholar
Corona, GL, Cucchi, ML, Frattini, P, et al.Noradrenergic output and clinical response in depressed women during amitriptyline therapy. Pharmacopsychiatry 1989; 22: 144–151CrossRefGoogle ScholarPubMed
Davidson, J, Giller, EL, Zisook, S, et al.An efficacy of isocarboxazid and placebo in depression and its relationship to depressive nosology. Arch Gen Psychiatry 1988; 45: 120–127CrossRefGoogle ScholarPubMed
Dunner, DL, Schmaling, KBTreatment of dysthymia: fluoxetine versus cognitive therapy. Neuropsychopharm 1994; 10: 234Google Scholar
Frances, A, Kocsis, J, Marin, D, Manning, D, Markowitz, J, Mason, B, Widiger, TDiagnostic criteria for dysthymic disorder. Psychopharmacol Bull 1989; 25: 325–329Google ScholarPubMed
Frances, A, Voss, CBTreatment planning, dysthymic disorder complicated by bouts of major depression. Hosp Community Psychiatry 1987; 38: 461–463Google ScholarPubMed
Garvey, MJ, Cook, BL, Tollefson, GD, Schaffer, CBAntidepressant response in chronic major depression. Compr Psychiatry 1989; 30: 214–217CrossRefGoogle ScholarPubMed
Geisler, A, Mygind, O, Knudsen, R, Sloth-Nielson, MRitanserin and flupenthixol in dysthymic disorder. Nord J Psychiatry 1992; 46: 237–243CrossRefGoogle Scholar
Guelfi, JD, Pichot, P, Dreyfus, JFEfficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 1989; 22: 41–48CrossRefGoogle ScholarPubMed
Gwirtsman, HEDysthymia, chronic depressive states: diagnostic and pharmacotherapeutic considerations. Overview of the diagnosis, prevalence, and comorbidity of dysthymia. Psychopharmacol Bull 1994; 30: 45–51Google ScholarPubMed
Harri son, W, Rabkin, J, Stewart, JW, Mcgrath, PJ, Tricamo, E, Quitkin, FPhenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986; 47: 346–349Google Scholar
Hellerstein, DJ, Yanowitch, P, Rosenthal, J, et al.A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150: 1169–1175Google ScholarPubMed
Hirschfeld, RMMajor depression, dysthymia and depressive personality disorder. Br J Psychiatry Suppl 1994 23–30CrossRefGoogle ScholarPubMed
Hirschfeld, RM, Schatzberg, AFLong-term management of depression. Am J Med 1994; 97: 33S38SCrossRefGoogle ScholarPubMed
Howland, RHPharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 1991; 11: 83–92CrossRefGoogle ScholarPubMed
Howland, RHChronic depression. Hosp Community Psychiatry 1993; 44: 633–639Google ScholarPubMed
Howland, RH, Thase, MEBiological studies of dysthymia. Biol Psychiatry 1991; 30: 283–304CrossRefGoogle ScholarPubMed
Jancar, J, Gunaratne, IJDysthymia and mental handicap. Br J Psychiatry 1994; 164: 691–693CrossRefGoogle ScholarPubMed
Keller, MBChronic and recurrent affective disorders: incidence, course, and influencing factors. Adv Biochem Psychopharmacol 1985; 40: 111–120Google ScholarPubMed
Keller, MBDysthymia in clinical practice: course, outcome and impact on the community. Acta Psychiatr Scand Suppl 1994; 383: 24–34CrossRefGoogle ScholarPubMed
Keller, MBTreatment of chronic depression with sertraline or imipramine: preliminary blinded response rates. Psychopharmacol Bull 1996; 25: 68–73Google Scholar
Keller, MB, Lavori, PW, Endicott, J, Coryell, W, Klerman, GL“Double depression”: two-year follow-up. Am J Psychiatry 1983; 140: 689–694Google ScholarPubMed
Keller, MB, Russell, CWRefining the concept of dysthymia. Hosp Community Psychiatry 1991; 42: 892–893Google ScholarPubMed
Klein, DN, Taylor, EB, Dickstein, S, Harding, KPrimary early-onset dysthymia: comparison with primary nonbipolar non-chronic major depression on demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome. J Abnorm Psychol 1988; 97: 387–398CrossRefGoogle Scholar
Kocsis, JH, Frances, AJ, Voss, C, Mann, JJ, Mason, BJ, Sweeney, JImipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253–257CrossRefGoogle ScholarPubMed
Kocsis, JH, Friedman, RA, Markowitz, JC, Leon, A, Miller, N, Gniwesch, L, Parides, MMaintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53: 769–774CrossRefGoogle ScholarPubMed
Kocsis, JH, Sutton, BM, Frances, AJLong-term follow-up of chronic depression treated with imipramine. J Clin Psychiatry 1991; 52: 56–59Google ScholarPubMed
Lecrubier, YThe treatment of dysthymics with a dopaminergic presynaptic blocker. Neuropsychopharm 1994; 10: 302Google Scholar
Lee, SThe nature of dysthymia [letter]. Br J Psychiatry 1995; 166: 678CrossRefGoogle Scholar
Leon, CA, Vigoya, J, Conde, S, Campo, G, Castrillon, E, Leon, AComparacion del efecto de la amisulprida y la viloxacina en el tratamiento de la distimia. Acta Psiquiatr Psicol Am Lat 1994; 40: 41–49Google Scholar
Maier, W, Benkert, OTreatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies. Psychopharmacology 1994; 115: 495–501CrossRefGoogle ScholarPubMed
Marin, DB, Kocsis, JH, Frances, AJ, Parides, MDesipramine for the treatment of “pure” dysthymia versus “double” depression. Am J Psychiatry 1994; 151: 1079–1080Google ScholarPubMed
Paykel, ES, Hollyman, JA, Freeling, P, et al.Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 1988; 14: 83–95CrossRefGoogle ScholarPubMed
Ravindran, AV, Bialik, RJ, Lapierre, YDTherapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 1994; 39: 21–26CrossRefGoogle Scholar
Reyntjens, A, Gelders, YG, Hoppenbrouwers, MJA, et al.Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 1986; 8: 205–211CrossRefGoogle Scholar
Rihmer, Z, Szadoczky, EDexamethasone suppression test and trh-tsh test in subaffective dysthymia and character-spectrum disorder. J Affect Disord 1993; 28: 287–291CrossRefGoogle ScholarPubMed
Rosenthal, J, Hemlock, C, Hellerstein, DJ, et al.A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 933–941CrossRefGoogle ScholarPubMed
Stewart, JW, Mcgrath, PJ, Liebowitz, MR, Harrison, W, Quitkin, F, Rabkin, JGTreatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42: 1148–1153CrossRefGoogle ScholarPubMed
Thase, ME, Fava, M, Halbreich, U, et al.A placebo-controlled randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777–784CrossRefGoogle ScholarPubMed
Tyrer, P, Murphy, S, Kingdon, D, et al.The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 1988; 2: 235–240CrossRefGoogle ScholarPubMed
Vallejo, J, Gasto, C, Catalan, R, Salamero, MDouble-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987; 151: 639–642CrossRefGoogle ScholarPubMed
Versiani, M, Nardi, AE, Figueira, ILV, Stahl, MTolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand 1990; 360: 24–28CrossRefGoogle ScholarPubMed
Versiani, M, Nardi, EDistimia: características clínicas y consecuencias Fraile, MG, Sánchez, JE, Pichot, PAvances en transtornos afectivos. Barcelona: Ediciones en Neurociencias; 1996; 33–48Google Scholar
Versiani, M, Nardi, E, Capponi, RMoclobemide compared with imipramine in the treatment of chronic depression (dysthymia DSM-III-R): a double-blind placebo controlled trial. Clin Neuropharmacol 1992; 15: 148–149Google Scholar
Ward, NG, Bloom, VL, Friedel, ROThe effectiveness of tricyclic and depressants in chronic depression. J Clin Psychiatry 1979; 40: 49–52Google Scholar
Waring, EM, Chamberlaine, CH, Mccrank, EW, Stalker, CA, Carver, C, Fry, R, Barnes, SDysthymia: a randomized study of cognitive marital therapy and antidepressants. Can J Psychiatry 1988; 33: 96–99CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.